Reliance’s Strand Life Sciences gets patent for blood-based early cancer detection
Strand Life Sciences, a subsidiary of Reliance Industries, has received an Indian patent for a blood-based early cancer detection platform. The technology uses cell-free DNA analysis and machine learning to identify cancer markers from a simple blood sample.
Why it matters
Advancements in liquid biopsy technology could significantly improve early cancer diagnosis rates and patient outcomes.
Strand Life Sciences, Bengaluru-based subsidiary of Reliance Industries Limited, on Tuesday (July 7, 2026) announced the grant of an Indian patent covering its integrated platform for early cancer detection using cell-free DNA (cfDNA) analysis.
The article provides a factual report on a corporate patent announcement.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in